ArticleCancer science2023
Probiotics enhances anti-tumor immune response induced by gemcitabine plus cisplatin chemotherapy for urothelial cancer.
Article in Cancer science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06904573 (A Multicenter, Randomized Controlled Phase II Study of Evaluating the Efficacy and Safety of Immunotherapy Combined With Oral Probiotics Compound), which is not on this map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multicenter, Randomized Controlled Phase II Study of Evaluating the Efficacy and Safety of Immunotherapy Combined With Oral Probiotics Compound (Biolosion) in Patients With Advanced Urothelial Carcinoma
Who cites it
28 citing papers in PubMed, 42 citations in OpenAlex.
- Exploring the gut microbiome and metabolomic interactions of antimetabolite drugs to optimize therapy.Gut microbes · 2026Review
- Microbiota as a modulator of drug response: targeting microbial-drug crosstalk in cancer therapy.Gut microbes · 2026Review
- Killing cancer takes guts: lessons learned from the manipulation of gut microbiome and immunotherapy for the future of urothelial carcinoma.Oncoimmunology · 2026Review
- The Potential Anticancer Mechanisms of Probiotics: A Comprehensive Review.Probiotics and antimicrobial proteins · 2026Review
- Fecal microbiota transplantation: a novel strategy and challenges in the adjuvant treatment of bladder Cancer.Frontiers in microbiology · 2026Review
- Review
- Exploring the Anticancer Potential of the Multistrain Probiotic FormulationAntioxidants (Basel, Switzerland) · 2025Article
- Gut microbiota and urological cancers: from microecological imbalance to potential for precision therapy.Discover oncology · 2025Review
- Gut microbiota and breast cancer risk: a Mendelian randomization study stratified by ER status.Discover oncology · 2025Article
- Probiotics: A New Approach for the Prevention and Treatment of Cervical Cancer.Probiotics and antimicrobial proteins · 2025Review
- [Multidimensional characteristics of the tumor microenviron-ment and advances in targeted delivery strategies].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2025Review
- Circulating metabolic biomarkers mediated causal relationship between gut microbiota and bladder cancer: a two-step mendelian randomization study.Discover oncology · 2025Article
- Genetically predicted plasma metabolites mediate the causal relationship between gut microbiota and osteosarcoma.Scientific reports · 2025Article
- Unlocking the Microbial Symphony: The Interplay of Human Microbiota in Cancer Immunotherapy Response.Cancers · 2025Review
- Microbiome and bladder cancer: the role of probiotics in treatment.Future microbiology · 2025Review
- From Microbial Homeostasis to Systemic Pathogenesis: A Narrative Review on Gut Flora's Role in Neuropsychiatric, Metabolic, and Cancer Disorders.Journal of inflammation research · 2025Review
- From dysbiosis to precision therapy: decoding the gut-bladder axis in bladder carcinogenesis.Frontiers in oncology · 2025Review
- Immune Checkpoint-Related Gene Polymorphisms and High Serum Concentration of PD-L1 and CTLA4 Contribute to the Resistance to Platinum-Based Chemotherapy in Cervical Cancer.International journal of women's health · 2025Article
- Carcinogen metabolism and bladder cancer: role of gut microbiota in disease and prevention.Frontiers in cellular and infection microbiology · 2025Review
- Microbiota and urinary tumor immunity: Mechanisms, therapeutic implications, and future perspectives.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 1 institution in 1 country.
Funding
Abstract
Chemotherapy drugs, such as gemcitabine and cisplatin (GC), are frequently administered to patients with advanced urothelial carcinoma, however the influence of the gut microbiota on their action is unclear. Thus, we investigated the effects of GC on the gut microbiome and determined whether oral supplementation with a probiotics mixture of Lactobacillus casei Shirota and Bifidobacterium breve enhanced the anti-tumor immune response. After subcutaneous inoculation with MBT2 murine bladder cancer cells, syngenic C3H mice were randomly allocated into eight groups. The gut microbiome cluster pattern was altered in both the GC and oral probiotics groups (p = 0.025). Both tumor-bearing conditions (no treatment) and GC chemotherapy influenced Pseudoclostridium, Robinsoniella, Merdimonas, and Phocea in the gut. Furthermore, comparison of the GC-treated and GC + probiotics groups revealed an association of four methyltransferase family enzymes and two short-change fatty acid-related enzymes with oral probiotics use. A significant difference in tumor volume was observed between the GC and GC + probiotics groups at week 2 of treatment. Additionally, decreased recruitment of cancer-associated fibroblasts and regulatory T cells, and activation of CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.